Experimental vaccine shows promise against dangerous intestinal illness

An experimental vaccine targeting enterotoxigenic Escherichia coli (ETEC), a major cause of severe diarrhea, has reached a development milestone and was licensed to Valneva. Researchers at the University of Bergen and Norwegian Research Center (NORCE) developed the technology, which shows promise in eliciting protective immune responses in children. The vaccine remains in development, requiring further trials and regulatory approval before public availability.